Mayo Clinic is one of the participants in a series C $35 million investment in Glooko, a diabetes data management startup.
Mountain View, Calif.-based Glooko said its solutions help more than 1 million patients served by more than 6,000 providers and a growing number of health plans around the world. Customers include Atrius Health, Allegheny Health Network, Stanford Health Care and Joslin Diabetes Center.
The company, founded in 2010, said its platform provides payers, employers, pharmaceutical companies and health systems with a diabetes digital health platform that delivers personalized and actionable insights to people with diabetes and their care teams.
Glooko said studies have found that using its mobile app has been associated with a drop in average blood glucose, estimated A1C (eA1C) and hyperglycemia rates in people with diabetes. Usage of the app was also associated with an increase in blood glucose test rate, the company added.
This funding round was led by Georgian Partners, a Toronto-based investor focused on applied analytics and machine learning. Besides Mayo Clinic, other investors include Insulet Corp., Canaan Partners, Social Capital, Medtronic and Samsung NEXT.
“This additional funding will help us to further our mission: to improve the lives of people with diabetes,” said Rick Altinger, CEO of Glooko, in a statement. “With this capital, we will accelerate our investments in clinical solutions that aim to increase medication adherence, provide personalized insights and prompts that drive behavior change for people with diabetes, and deliver clinical decision support to thousands of clinicians and coaches so they can better support people with diabetes in between office visits.”
